Novo Nordisk nails another phase III study of once-weekly insulin
Results from a late-stage study of insulin icodec show that type 2 diabetes patients were better off on the Danish drugmaker’s experimental drug combined with an app solution than with standard treatment.
by mikkel aabenhus hemmingsen, translated by daniel pedersen
On Monday, Novo Nordisk announced a success, reporting positive top-line results for a phase IIIa trial of once-weekly insulin icodec in a company press release.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
.jpg)
Novo Nordisk has twin successes with once-weekly insulin
For subscribers
